Literature DB >> 18331779

Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.

P Kanellou1, A Zaravinos, M Zioga, A Stratigos, S Baritaki, G Soufla, O Zoras, D A Spandidos.   

Abstract

Actinic keratosis (AK) is a well-established pre-cancerous skin lesion that has the potential to progress to squamous cell carcinoma (SCC). We investigated the involvement of the CDKN2A, CDKN2B and p53 genes in AK and in the progression of AK to SCC. Mutational analysis on exons 1a, 1b and 2 of the CDKN2A locus and exon 1 of the CDKN2B locus as well as allelic imbalance was performed in 26 AK specimens. Expression levels of the genes p14(ARF), p15(INK4b), p16(INK4a) and p53 were examined in 16 AKs and 12 SCCs by real-time RT-PCR. A previously described polymorphism of p16(INK4a) (Ala148Thr) was detected at an allelic frequency of 12%. Six samples carried novel mutations at codon 71 of the CDKN2A locus and one sample presented an additional mutation at codon 65. Two AK samples carried a not-previously described non-UV type missense mutation at codon 184 (Val184Glu) of exon 1b in the p14(ARF) gene. Regarding the CDKN2B locus a new mutation at codon 50 (Ala50Thr) and another at codon 24 (Arg24Arg), were detected. Microsatellite instability (MSI) was found in 15% of AKs in at least one marker, indicating that genetic instability has some implication in the development of AK. Down-regulation of p16(INK4a) and p53 mRNA levels was noted in SCC compared to AK. TSGs expression levels in sun-exposed morphologically normal-appearing skin, suggests that abnormal growth stimuli might exist in these tissues as well. Furthermore, we suggest a possible role of p15(INK4b), independently from the intracellular pathway mediated by p16(INK4a), and of p14(ARF) in AK development, as well as in the progression of AK to SCC. The deregulation of the expression profiles of the CDKN2A, CDKN2B and p53 genes may, independently of mutations and LOH at 9p21, play a significant role in AK and progression of AK to SCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18331779     DOI: 10.1016/j.canlet.2008.01.042

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  23 in total

1.  Genetic variability of the distal promoter of the ST2 gene is associated with angiographic severity of coronary artery disease.

Authors:  Andy Tsapaki; Apostolos Zaravinos; Stavros Apostolakis; Konstantinos Voudris; Konstantina Vogiatzi; Georgios E Kochiadakis; Demetrios A Spandidos
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

2.  Aberrant promoter methylation of p15 (INK⁴b) and p16 (INK⁴a) genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis.

Authors:  Xuan Wang; Yan-Bin Zhu; Hai-Peng Cui; Ting-Ting Yu
Journal:  Tumour Biol       Date:  2014-06-08

3.  Activation of S6 signaling is associated with cell survival and multinucleation in hyperplastic skin after epidermal loss of AURORA-A Kinase.

Authors:  Weston Kenneth Ryan; Josiah Fernandez; Mikayla Katherine Peterson; David William Sheneman; Brendan Keefe Podell; Subhajyoti De; Enrique Carlo Torchia
Journal:  Cell Death Differ       Date:  2018-07-26       Impact factor: 15.828

4.  Genetic alterations of RD(INK4/ARF) enhancer in human cancer cells.

Authors:  Junan Li; Thomas J Knobloch; Ming J Poi; Zhaoxia Zhang; Andrew T Davis; Peter Muscarella; Christopher M Weghorst
Journal:  Mol Carcinog       Date:  2012-10-12       Impact factor: 4.784

5.  P14ARF deficiency and its correlation with overexpression of p53/MDM2 in sporadic vestibular schwannomas.

Authors:  Ying Chen; Zhao-Yan Wang; Hao Wu
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-26       Impact factor: 2.503

6.  A genetic variant of Aurora kinase A promotes genomic instability leading to highly malignant skin tumors.

Authors:  Enrique C Torchia; Yiyun Chen; Hong Sheng; Hiroshi Katayama; James Fitzpatrick; William R Brinkley; Carlos Caulin; Subrata Sen; Dennis R Roop
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

Review 7.  How to treat actinic keratosis? An update.

Authors:  Claudia Costa; Massimiliano Scalvenzi; Fabio Ayala; Gabriella Fabbrocini; Giuseppe Monfrecola
Journal:  J Dermatol Case Rep       Date:  2015-06-30

8.  Genomic instability in human actinic keratosis and squamous cell carcinoma.

Authors:  Luciana Sanches Cabral; Cyro Festa Neto; José A Sanches; Itamar R G Ruiz
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

9.  Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.

Authors:  C J Jennings; B Murer; A O'Grady; L M Hearn; B J Harvey; E W Kay; W Thomas
Journal:  Br J Cancer       Date:  2015-06-09       Impact factor: 7.640

10.  New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel.

Authors:  Brian Berman
Journal:  Clin Cosmet Investig Dermatol       Date:  2012-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.